HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Infirst Expects Dr. Cocoa OTCs To Win Over Children And Parents

This article was originally published in The Tan Sheet

Executive Summary

CEO Manfred Scheske believes cocoa flavoring gives Dr. Cocoa an edge in the children’s OTC space, where competitors already offer flavors in many products. Experts says flavors make taking a medicine more appealing to children, but some question whether flavors should be used.

You may also be interested in...



Glaxo Veteran Directs Infirst’s Jump Into Differentiated OTCs

U.K. biotech SEEK launches infirst HEALTHCARE to focus on commercializing consumer products, while the firm’s pipeline continues developing. Former GlaxoSmithKline exec Manfred Scheske leads infirst as it prepares cough remedy and analgesic launches in multiple markets.

Infirst Expects Dr. Cocoa OTCs To Win Over Children And Parents

CEO Manfred Scheske believes cocoa flavoring gives Dr. Cocoa an edge in the children’s OTC space, where competitors already offer flavors in many products. Experts says flavors make taking a medicine more appealing to children, but some question whether flavors should be used.

New Products In Brief: MacuDrop, Clearwayz, Adiri MD+ and more

Macular Health launches MacuDrop AREDS II; Clearwayz supplement supports sinuses; Supplement beverage for bariatric patients; Adiri MD+ Nurser for accurate dosing; BabyB targets cause of rashes; more New Products In Brief

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS124007

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel